5-Alpha Reductase Deficiency Market Report 2026

5-Alpha Reductase Deficiency Market Overview

• 5-Alpha Reductase Deficiency market size has reached to $1.5 billion in 2025 • Expected to grow to $2.36 billion in 2030 at a compound annual growth rate (CAGR) of 9.5% • Growth Driver: Research And Development Activities Propel Advancements In The 5-Alpha Reductase Deficiency Market • Market Trend: Emerging Trends In Genetic Testing For 5-Alpha Reductase Deficiency • North America was the largest region in 2025.

What Is Covered Under 5-Alpha Reductase Deficiency Market?

5-alpha reductase deficiency is a disorder which affects male sexual development both before and during puberty. Dihydrotestosterone, a crucial hormone for male sexual development, is not sufficiently produced in people suffering from 5-alpha reductase deficiency. The major diagnosis of 5-alpha reductase deficiency is chromosome analysis, gene sequencing, hormone tests, imaging tests, genetic screening, and others. Chromosome analysis is used to diagnose 5-alpha reductase deficiency to determine whether the patient has XX (Female) or XY (Male) chromosomes. The treatments include surgery, vaginoplasty, feminizing genitoplasty, hormone replacement therapy, and others. The end-users include hospitals, specialty clinics, and others.

What Is The 5-Alpha Reductase Deficiency Market Growth Forecast?

The 5-alpha reductase deficiency market size is expected to see strong growth in the next few years. It will grow to $2.36 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to advancements in gene sequencing technologies, rising newborn and carrier screening programs, increasing focus on personalized hormone therapy, growth in specialty clinics for rare disorders, expanding research in genetic endocrinology. Major trends in the forecast period include increasing early diagnosis of 5-alpha reductase deficiency, rising awareness of disorders of sexual development, growing adoption of genetic and hormonal testing, expansion of specialized endocrinology and urology care, improved access to hormone replacement therapies.

Global 5-Alpha Reductase Deficiency Market Segmentation

1) By Diagnosis: Chromosome Analysis, Gene Sequencing, Hormone Tests, Imaging Tests, Genetic Screening, Other Diagnosis 2) By Treatment: Surgery, Vaginoplasty, Feminizing Genitoplasty, Hormone Replacement Therapy, Other Treatments 3) By End-Users: Hospitals, Specialty Clinics, Other End-Users Subsegments: 1) By Chromosome Analysis: Karyotyping, Fluorescence In Situ Hybridization (FISH) 2) By Gene Sequencing: Targeted Gene Panels, Whole Exome Sequencing 3) By Hormone Tests: Testosterone Levels, Dihydrotestosterone (DHT) Levels 4) By Imaging Tests: Ultrasound, MRI 5) By Genetic Screening: Carrier Testing, Newborn Screening 6) By Other Diagnosis: Clinical Evaluation, Family History Assessment

What Is The Driver Of The 5-Alpha Reductase Deficiency Market?

The growing number of research and development activities in genomics is significantly contributing to the growth of the 5-alpha reductase deficiency market. Genomics refers to studying a person's whole gene pool (genome), including how those genes interact with one another and with their environment. Genomics is used to diagnose 5-alpha reductase deficiency by identifying specific genetic mutations responsible for the disorder. Thus, research and development activities in genomics will aid in discovering and treating the disorder. For instance, in February 2025, according to the National Center for Science and Engineering Statistics (NCSES), a US-based government statistical agency, U.S. research and development expenditures rose from $892 billion in 2022 to $940 billion in 2023, reflecting an increase of $48 billion. Therefore, the growing number of research and development activities in genomics will drive the 5-alpha reductase deficiency industry.

Key Players In The Global 5-Alpha Reductase Deficiency Market

Major companies operating in the 5-alpha reductase deficiency market are F. Hoffmann-La Roche Ltd, Sanofi SA, Pfizer Inc, GlaxoSmithKline plc, Novartis AG, Bayer AG, Eli Lilly and Company, Johnson and Johnson Services Inc, Novo Nordisk A S, Regeneron Pharmaceuticals Inc, Roivant Sciences Ltd, Sanofi Genzyme, Shionogi and Co Ltd, Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, UCB S A, Vertex Pharmaceuticals Incorporated, Cadila Healthcare Limited, Endo International plc

Global 5-Alpha Reductase Deficiency Market Trends and Insights

Major companies operating in the 5-alpha reductase deficiency market are focusing on developing technologically advanced products, such as consumer-initiated genetic tests, to allow individuals to obtain personal genetic information directly and privately without the need for a healthcare provider's referral. A consumer-initiated genetic test is a type of genetic testing that individuals order directly from a laboratory or testing company, typically without the involvement of a healthcare provider, to gain insights into their genetic predispositions, ancestry, or health-related traits. For instance, in July 2023, Quest Diagnostics, a US-based provider of diagnostic information services, launched Genetic Insights, a consumer-initiated genetic test. The new offering helps individuals assess their potential risk of developing certain hereditary health conditions. It features advanced technology and comprehensive support, including personalized health reports and access to genetic counseling. By analyzing a saliva sample, Genetic Insights evaluates 36 genes to identify the risk of nearly two dozen hereditary conditions, such as breast and colon cancer, various heart and blood disorders, as well as carrier status for cystic fibrosis, sickle cell anemia, and Tay-Sachs disease. This test is designed to fill the gaps left by existing consumer genetic tests and utilizes cutting-edge next-generation sequencing (NGS) technology, which can analyze thousands of DNA variants in disease-related genes and examines more regions of a person's genome compared to traditional microarray testing.

What Are Latest Mergers And Acquisitions In The 5-Alpha Reductase Deficiency Market?

In April 2023, Blue Water Vaccines Inc., a US-based biopharmaceutical company, acquired ENTADFI (finasteride/tadalafil) from Veru Inc. for approximately $100 million. Through the acquisition, the company's scope to include many pharmaceutical sectors is expanded. This acquisition allows Blue Water to go into the commercial arena while offsetting burn and providing critical income to the vaccine candidate pipeline. Blue Water's primary objective of assisting people in need remains strong and unwavering, and we look forward to expanding this asset and the pipeline for patients worldwide. Veru Inc. is a US-based biopharmaceutical company that offers ENTADFI (finasteride/tadalafil), which is used to target the enzyme 5-alpha-reductase.

Regional Outlook

North America was the largest region in the 5-alpha reductase deficiency market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the 5-Alpha Reductase Deficiency Market?

The 5-alpha reductase deficiency market includes revenues earned by entities by providing ultrasound screening diagnosis and surgical procedures to treat 5-alpha reductase deficiencies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the 5-Alpha Reductase Deficiency Market Report 2026?

The 5-alpha reductase deficiency market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the 5-alpha reductase deficiency industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.